© 1990 by Oxford University Press
Journal of the National Cancer Institute, Vol. 82, No. 3, 208-212,
February 7, 1990
© 1990 Oxford University Press
Phase II Study of Recombinant Human Interferon Gamma for Treatment of Cutaneous T-Cell Lymphoma
Veterans Administration Lakeside Medical Center Chicago, IL
Department od Medicine, Division of Medical Oncology Denver, Co
Department of Dermatology, University of Colorado Cancer Center Denver, Co
Gnentech Inc. San Franciso, CA
*Correspondence to: Edward H. Kaplan, M.D., Rush-Presbyterian-St. Luke's Medical Center, Department of Medical Oncology, 1725 W. Harrison, Suite 830, Chicago, IL 60612.
Recombinant human interferon gamma (rIFN- 
) was used for the treatment of 16 patients with various stages of cutaneous T-cell lymphoma (CTCL). All patients had been previously treated with standard topical and/or systemic therapies, and some had received experimental treatment with retinoids, recombinant human interferon alfa-2a (rIFN-
2a), or radiolabeled monoclonal antibodies; most patients had an advanced stage of disease. Objective partial responses (PRs) were noted in five patients (31%) and lasted 3 months to greater than 32 months (median, 10 mo). One of these five patients had previously had disease progression after an initial PR with rIFN-2a. Six other patients (38%) showed minor or mixed responses. The most common side effects of rIFN- included fever, weight loss, mild neutropenia, elevated lac-tate dehydrogenase, and elevated hepatic transaminases. Additionally, one episode of nephrotic syndrome and one cutaneous allergic reaction were noted. None of the toxic effects were life threatening, and all were reversible. These results suggest that rIFN-has efficacy in the treatment of CTCL refractory to rIFN-2a. [J Natl Cancer Inst 82: 208–212, 1990]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. M. Prince, S. Whittaker, and R. T. Hoppe How I treat mycosis fungoides and Sezary syndrome Blood, November 12, 2009; 114(20): 4337 - 4353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Smith, J. S. Moylan, J. D. Smith, W. Li, and M. B. Reid IFN-{gamma} does not mimic the catabolic effects of TNF-{alpha} Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1947 - C1952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-i. Yamanaka, R. Clark, R. Dowgiert, D. Hurwitz, M. Shibata, B. E. Rich, K. Hirahara, D. A. Jones, S. Eapen, H. Mizutani, et al. Expression of Interleukin-18 and Caspase-1 in Cutaneous T-Cell Lymphoma Clin. Cancer Res., January 15, 2006; 12(2): 376 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. McGinnis, R. Ubriani, S. Newton, J. M. Junkins-Hopkins, C. C. Vittorio, E. J. Kim, M. Wysocka, and A. H. Rook The Addition of Interferon Gamma to Oral Bexarotene Therapy With Photopheresis for Sezary Syndrome Arch Dermatol, September 1, 2005; 141(9): 1176 - 1178. [Full Text] [PDF]
|
|
|
|
|
|
R. Dummer, J. C. Hassel, F. Fellenberg, S. Eichmuller, T. Maier, P. Slos, B. Acres, P. Bleuzen, V. Bataille, P. Squiban, et al. Adenovirus-mediated intralesional interferon-{gamma} gene transfer induces tumor regressions in cutaneous lymphomas Blood, September 15, 2004; 104(6): 1631 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Willers, R. Dummer, W. Kempf, T. Kundig, G. Burg, and M. E. Kadin Proliferation of CD30+ T-Helper 2 Lymphoma Cells Can Be Inhibited by CD30 Receptor Cross-Linking with Recombinant CD30 Ligand Clin. Cancer Res., July 1, 2003; 9(7): 2744 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]
|
|
|
|
|
|
M. H. Vermeer, C. P. Tensen, P. M. van der Stoop, H. W. van Oostveen, M. Lund, R. J. Scheper, and R. Willemze Absence of TH2 Cytokine Messenger RNA Expression in CD30-Negative Primary Cutaneous Large T-Cell Lymphomas Arch Dermatol, July 1, 2001; 137(7): 901 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Siegel, T. Pandolfino, J. Guitart, S. Rosen, and T. M. Kuzel Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts J. Clin. Oncol., August 15, 2000; 18(15): 2908 - 2925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Chang and B. Bistrian Review: The Role of Cytokines in the Catabolic Consequences of Infection and Injury JPEN J Parenter Enteral Nutr, May 1, 1998; 22(3): 156 - 166. [Abstract] [PDF]
|
|
|
|
|
|
E. R. Hansen Immunoregulatory Events in the Skin of Patients With Cutaneous T-Cell Lymphoma Arch Dermatol, May 1, 1996; 132(5): 554 - 561. [Abstract] [PDF]
|
|
|
|
|
|
J. P. Marolleau, M. Baccard, B. Flageul, M. Rybojad, L. Laroche, O. Verola, M. Brandely, P. Morel, and C. Gisselbrecht High-Dose Recombinant Interleukin-2 in Advanced Cutaneous T-Cell Lymphoma Arch Dermatol, May 1, 1995; 131(5): 574 - 579. [Abstract] [PDF]
|
|
|
|
|
|
A. H. Rook, B. R. Vowels, C. Jaworsky, A. Singh, and S. R. Lessin The Immunopathogenesis of Cutaneous T-Cell Lymphoma: Abnormal Cytokine Production by Sezary T Cells Arch Dermatol, April 1, 1993; 129(4): 486 - 489. [Abstract] [PDF]
|
|
|
|
 |
|
 C. M. Lindley and T. R. Gordon Application of Biotechnology Products in Oncology Journal of Pharmacy Practice, January 1, 1991; 4(2): 117 - 130. [PDF]
|
|